公开(公告)号：EP3052517A4

公开(公告)日：2017-07-26

申请号：EP14846993

申请日：2014-09-30

申请人： LOS ALAMOS NAT SECURITY LLC ,  UNIV OXFORD INNOVATION LTD

发明人： KORBER BETTE T M ,  HANKE TOMAS ,  MCMICHAEL ANDREW

IPC分类号： C07K14/15 ,  A61K39/21

CPC分类号： A61K39/21 ,  A61K39/12 ,  C07K14/005 ,  C12N2740/16034

摘要： Disclosed herein are mosaic conserved region HIV polypeptides and immunogenic polypeptides including one or more of the mosaic conserved region polypeptides. In some embodiments, the immunogenic polypeptides are included in an immunogenic composition, such as a polyvalent immunogenic composition. Also disclosed herein are methods for treating or inhibiting HIV in a subject including administering one or more of the disclosed immunogenic polypeptides or compositions to a subject having or at risk of HIV infection. In some embodiments, the methods include inducing an immune response in a subject comprising administering to the subject at least one of the disclosed immunogenic polypeptides or a nucleic acid encoding at least one of the immunogenic polypeptides.

摘要翻译： 本文公开了马赛克保守区HIV多肽和免疫原性多肽，包括一个或多个马赛克保守区多肽。 在一些实施方案中，免疫原性多肽包含在免疫原性组合物中，例如多价免疫原性组合物。 本文还公开了用于治疗或抑制受试者中的HIV的方法，其包括将一种或多种所公开的免疫原性多肽或组合物给予患有HIV感染或具有感染HIV风险的受试者。 在一些实施方案中，所述方法包括在受试者中诱导免疫应答，包括向受试者施用至少一种所公开的免疫原性多肽或编码至少一种免疫原性多肽的核酸。

公开(公告)号：EP3200878A4

公开(公告)日：2018-05-30

申请号：EP15847978

申请日：2015-10-05

申请人： LOS ALAMOS NAT SECURITY LLC ,  UNIV OREGON HEALTH & SCIENCE ,  VIR BIOTECHNOLOGY INC

发明人： BRUENING ERIC ,  FRUEH KLAUS ,  PICKER LOUIS ,  KORBER BETTE T M ,  THEILER JAMES ,  MARSHALL EMILY

IPC分类号： A61P31/18 ,  A61K39/21

CPC分类号： A61K39/12 ,  A61K39/21 ,  A61K2039/53 ,  A61K2039/70 ,  C12N2710/16143 ,  C12N2740/16034 ,  C12N2740/16234

摘要： Provided herein are HIV-1 vaccines comprising a carrier and a population episensus antigen determined using the EpiGraph approach. Also provided are HIV-1 vaccines comprising a carrier, a population episensus antigen, and a tailored antigen. Also provided are methods of designing and producing an HIV-1 vaccine for a subject comprising designing vaccine antigens to optimally cover the diversity within a geographic area using an antigen amino acid sequence generated using the EpiGraph approach, and producing said designed vaccine antigen. Also provided are methods of inducing an effector memory T cell response comprising designing the one or more EpiGraph amino acid sequences, producing a vaccine comprising the one or more EpiGraph amino acid sequences and a vector, and administering the vaccine to a subject. Further provided are methods of treating HIV-1 in a subject comprising administering an effective amount of the described HIV-1 vaccines to the subject in need thereof.